Skip to main content
  • PCSK9 Drugs' Hurdles Coming Down Slowly

    Prices dropped, prescriptions rose in 2018 -- but it's still not a clear track

    The landmark ODYSSEY Outcomes trial reported last March showed a hard clinical outcomes advantage and all-cause mortality reduction with alirocumab (Praluent). You can read MedPage Today's summary here. In this follow-up we examine how the trial has affected practice since then.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details